Valneva SE 6-K, filed Nov 8, 2022
Valneva SE (VALN)
About this 6-K
Valneva SE filed this 6-K on November 8, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: November 8, 2022
Commission File Number: 001-40377
Valneva SE
(Translation of registrant's name into English)
6 rue Alain Bombard
44800 Saint-Herblain, France
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
On November 7, 2022, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information contained in this Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the registrant's Registration Statement on Form F-3 (File No. 333-266839).
| Exhibit | ||
| 99.1 | Press release dated November 7, 2022 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Valneva SE | ||
| (Registrant) | ||
| Date: November 8, 2022 | /s/ Thomas Lingelbach | |
| Thomas Lingelbach | ||
| Chief Executive Officer and President | ||
EXHIBIT 99.1
Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference
Saint-Herblain (France), November 7, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its Chief Executive Officer Thomas Lingelbach and Chief Financial Officer Peter Bühler will present and participate in 1-on-1 meetings with institutional investors at the Jefferies London Healthcare Conference, to take place November 15-17, 2022 in London, England.
Additionally, Mr. Lingelbach and Mr. Bühler will participate in a fireside chat on Tuesday, November 15, 2022, at 11:30am GMT, to discuss the Company’s late-stage vaccine candidates against chikungunya (VLA1553) and Lyme disease (VLA15), as well as its commercial products. The webcast will be accessible live via the following link, https://wsw.com/webcast/jeff255/valn/1856007. A replay of the webcast will be available following the live events in the “Investor” section of the Valneva website at www.valneva.com.
To request a meeting at the event, please contact your representative at Jefferies.
About Valneva SE
Valneva is a specialty vaccine company focused on the development and commercialization
of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted
approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing
these diseases. Valneva has leveraged its expertise and capabilities both to successfully commercialize three vaccines and to rapidly
advance a broad range of vaccine candidates into the clinic, including candidates against Lyme disease and the chikungunya virus.
| Valneva Investor and Media Contacts Laetitia Bachelot-Fontaine VP, Global Communications and European Investor Relations M +33 (0)6 4516 7099 communications@valneva.com |
Joshua Drumm, Ph.D. VP, Global Investor Relations M +001 917 815 4520 joshua.drumm@valneva.com |
|
|
Forward-Looking Statements
This press release contains certain forward-looking statements relating
to the business of Valneva, including with respect to possible regulatory submissions and approval of VLA1553, and timing and plans for
clinical programs and product candidates. In addition, even if the actual results or development of Valneva are consistent with the forward-looking
statements contained in this press release, those results or developments of Valneva may not be indicative of future results. In some
cases, you can identify forward-looking statements by words such as “could,” “should,” “may,” “expects,”
“anticipates,” “believes,” “intends,” “estimates,” “aims,” “targets,”
or similar words. These forward-looking statements are based on the current expectations of Valneva as of the date of this press release
and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance
or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking
statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties involved in the development
and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency
fluctuations, the impact of the global and European credit crisis, the ability to obtain or maintain patent or other proprietary intellectual
property protection and the impact of the COVID-19 pandemic. In light of these risks and uncertainties, there can be no assurance that
the forward-looking statements made in this press release will in fact be realized. Valneva is providing the information in this press
release as of the date hereof and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether
as a result of new information, future events, or otherwise.